Tag: SAPX

FOLD, MWIP & Extended Watchlist

FOLD caught our attention yesterday as an intriguing pharmaceutical play that recently underwent some panic selling, and is now coming off of the resultant bottom.First a little back-story: Amicus has been teamed up with pharma giant, GlaxoSmithKline (GSK), running clinical trials on a drug called migalastat HCI, meant to treat a rare disease in which a genetic mutation prevents enzymes from breaking down a fatty substance referred to as GL-3. As a result, GL-3 build up in the kidneys can lead to organ failure and death.

The big sell-off occurred back in late December when the duo announced that the study, statistically, failed to meet their objectives after a 6 month period, making a fast-track to FDA approval an impossibility.

The encouraging news, and the reason we think now is a prime time to take a look at FOLD, is that the studies do not conclude at the 6 month point; they have continued, and the 12 month results are expected to come early in 2013. While failing to meet project goals, there was still a 50% reduction in GL-3 buildup in 41% of the migalastat HCI group, as compared to just 28% of the placebo group. The 12-month results will be accompanied by the company meeting FDA officials to discuss the track to approval, and how it is altered by the results of trials still underway.

John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 9, 2013 at 3:00 p.m. PT. which can be viewed via a LIVE WEBCAST on the specified date and time.

What really jumps out to us, is simply the fact that FOLD recently saw a big gap down, and has now begun to recover. Often in the past we’ve seen cases such as this where the stock bounces back to fill the gap, offering up great opportunities for gain.

It could also come to that sooner, rather than later- The company also has other irons in the fire, as this morning it released a PR regarding another of its drugs currently in testing phases, this time with positive results:


Amicus Therapeutics Announces Positive Results From All Four Cohorts in Phase 2 Chaperone-Enzyme Replacement Therapy (ERT) Co-Administration Study for Pompe Disease

CRANBURY, N.J., Jan 04, 2013 (GLOBE NEWSWIRE via COMTEX) — Strong Proof-of-Concept Data for Chaperone’s Ability to Stabilize and Enhance Activity and Uptake of Currently Marketed ERT Products for Pompe Disease

Results to be Presented at LDN WORLD Symposium in February 2013

Initiation of Repeat-Dose Pompe Study Anticipated in 3Q13

Amicus Therapeutics (Nasdaq: FOLD) today announced positive preliminary results from all 4 dose cohorts in a Phase 2 study (Study 010) to evaluate the safety and pharmacokinetic (PK) effects of the pharmacological chaperone AT2220 (duvoglustat HCl) co-administered with enzyme replacement therapy (ERT) for Pompe disease (Myozyme and Lumizyme). Myozyme and Lumizyme (alglucosidase alfa, or recombinant human GAA enzyme, rhGAA) are the first and only approved treatments for Pompe disease.

___

We will be continuing to follow this play, and keep everyone updated as more details arise.

___

MediSwipe, Inc. MWIP

A lot of you may have missed our last report before the holidays, in which we mentioned that we would like to see MWIP continue to hold support above a penny and test its previous highs. Yesterday saw the stock break past its previous high of .0199 into blue-sky territory, hitting a high of .0289, earning us a spot on the Penny Stock Rumble with a gain of 50%

In total, from the low following our first mention of MWIP back at .0024, yesterday’s high marks an astonishing 1104% gain.

If and when we see a pullback on MWIP, we want to see the previous resistance of .0199 hold as a future level of support for us to remain bullish.

___

Extended Watchlist:

UNLA, AHFD, AXCG, SAPX, SFAZ, ZLCS

GMXS, ERBB & Extended Watchlist

Gemini Explorations, Inc. GMXS

GMXS is an old-time favorite of ours, which reappeared on our extended watchlists on Friday, November 16th, after we observed the stock coming off of its bottom one day prior. Those of you who have been following us for some time may recall that this is the play we followed from .04-.10 back in March.

On the 16th, GMXS was as low as .03, and closed at the high of .04. Last week we continued to see slow and steady gains, finishing off the week at .059. As we stated in an afternoon update last Monday, we could be looking at a re-test of the previous ten-cent high.

The indicators on the chart are looking strong, with a possible golden cross in the making. The RSI is in the power zone, suggesting that recent momentum could continue.

____

 

Tranzbyte Corp ERBB

Since we did our follow-upon our initial medical marijuana round-up report, we’ve been sure to continue to include ERBB in the stocks we are tracking. On the 31st following our alert, we saw a .0016 low before witnessing a jump to .013 (+713%). It slid back and found support above the 20DMA, bounced off of .0035 and hit a subsequent high of .007 this past Wednesday.We’ve been calling for a golden cross since the 13th, stating: “we have a golden cross formation setting up on the chart. This play will be on our watchlist for weeks to come.” The 20DMA also has a chance to break the 200DMA as predicted, possibly this week. Once we see that occur, we expect to see some major upward momentum in the stock.

____

Extended Watchlist:

SRGE, SAPX, TLFX, EGCT,

 

SAPX, EXTO, PROT – Today’s Watchlist

Proteonomix, Inc. PROT

PROT hit a high of 4.00 on Tuesday, before receding back to 3.20. With all of the gains that the stock has been racking up, it is to be expected to see a bit of a course correction here or there. So, much like some of the other stocks on our watchlist, we are sitting in careful observer mode in order to eye the next possible entry point.

Exit Only, Inc.EXTO

As we’ve seen before, and stated in yesterday’s newsletter, there is going to be a bit of resistance in the .008-.009 range, but we are still counting on EXTO to break over a penny. In all honesty, we believe that EXTO could attain new highs in 2012 (previous high .0129)

Seven Arts Entertainment, Inc. SAPX

SAPX remains high on our watchlist this mid week, after it was confirmed on Tuesday that the company will be acquiring two as yet unreleased albums by multi-platinum recording artist, DMX.
LOS ANGELES, CA, Jan 24, 2012 (MARKETWIRE via COMTEX) — Seven Arts Entertainment Inc. (NASDAQ: SAPX) (“Seven Arts”) announced today that it has executed a definitive agreement with David Michery to acquire his music assets. Mr. Michery is a music industry veteran with an extensive track record of accomplishments. The acquired Michery assets are comprised of recording agreements with several artists, including two completed albums with multi-platinum artist DMX. Seven Arts also announced that “Undisputed,” the first of these two completed DMX albums, is scheduled to be released in the United States in the second quarter of 2012 through Fontana Distribution, a division of Universal Music Group
.

We are of course still monitoring all of the stocks that have appeared on our watchlists recently, which in addition to today’s featured stocks, include SVMI, VHGI, BNVI.

PROT, EXTO, SVMI, SAPX, VHGI, BNVI – Today’s Stock Watchlist

Every single one of our picks was in the green on Monday kicking off the week right, for combined gains of 79%!

Proteonomix, Inc. PROT

Having recently experienced a golden cross, PROT awoke like a sleeping giant to bring us gains on the order of 1000% in the past month. As if that wasn’t more than adequate, on Monday, the stock continued to trade like a beast, racking up further gains of nearly 40% In the past three days, PROT is up over 100%  With the strength heading into yesterday’s close, we wouldn’t be shocked to find that momentum continuing this morning with a gap-up, followed by an additional run.

Exit Only, Inc. EXTO

EXTO enjoyed its fourth consecutive day of appreciation on higher than average volume. Once we breach the .008-.009 range, it looks to be smooth sailing through to a penny. Anticipation for the name and symbol change is indeed building, and once that transpires, we could see a new wave of investors begin to accumulate the stock. We will keep you apprised.

SaVi Media Group, Inc. SVMI

The chart SVMI is shaping up quite nicely, and volume has been quite strong for the past two sessions. A move from .0083 to .009 put its modest gain for the day at just over 8% There seems to be some resistance at .009, but once broken through, there is room for more gains. As we proved with PROT, sometimes these things take more than just a few days to produce, and we are still fairly confident in the case of SVMI.

Seven Arts Entertainment, Inc. SAPX

We have seen three consecutive days of increases for SAPX. On Monday, the stock crept up 10% on greater-than-average volume. The high on Monday was .50, which, from the previous low following our call, (.271) made a possible gain of 85%

VHGI Holdings, Inc. VHGI

 VHGI is our energizer bunny stock, just going, and going.. The stock has produced gains for 4 out of the last 5 days, with seemingly no end in sight. It added 10% to its gains on Monday.

BioNovo, Inc. BNVI

This play is turning out exactly as anticipated, seeing two days of gains in a row. From Friday’s low at .1512  to yesterday’s peak at .218, the stock gained 44%

VHGI, SAPX, SVMI, BNVI, EXTO – Today’s Stock Watchlist

3 out of 4 of our picks on Friday closed in the green, continuing a pattern of excellence for us in 2012. Where else can you find so many successful picks on such a regular basis? The answer, (and believe us, we’ve checked around) is nowhere!

Exit Only, Inc. EXTO

EXTO made yet another swing on Friday, as has become commonplace; we seem to witness these swings on a week-to-week basis. The range last week was from .0053-.0075, making an intraweek gain of 42% possible. Still no word on the new symbol to accompany the name change, but we will keep you all apprised.

BioNovo, Inc. BNVI

BNVI is a bottom play from last week with a chart that is still looking ripe to yield substantial gains moving forward. As you can see, it is exhibiting three of our favorite bottomplay characteristics at present, by the chart we’ve included below:

SaVi Media Group, Inc. SVMI

SMVI was the one pick from Friday that needed a little more time to make its move, but we still have it on our radar. We really like the Dyna- Valve technology behind this company, a product aimed at reducing carbon emissions, fuel consumption, and engine wear in motor vehicles. Anything aiming to produce those kinds of results is worth taking the time to monitor.

Seven Arts Entertainment, Inc. SAPX

Once again, we were early to the party on a runner. While having already amassed gains of 54% , SAPX was the subject of a big promotion over the weekend, and we expect even more gains to roll in. We are still calling for this stock to make a run at recent highs in the .63-.67 range.

VHGI Holdings, Inc. VHGI

VHGI has brought us gains well into the triple-digits since we began following, back on Dec. 9th. On Friday, the stock reached another 52-wk high, which reaffirms the fact that we are in bluesky territory, and there is no telling where the ceiling is on this thing!

Get Our FREE Daily Reports!

SUBSCRIBE